Eptinezumab is a medicine that helps prevent migraines in adults. It is given as an infusion into a vein, usually every three months. It works by blocking a protein called CGRP that plays a part in causing migraine attacks.
Every report comes from a Lived member, sent anonymously.
Have you tried Vyepti (Eptinezumab) for Migraines?
Eptinezumab, sold as Vyepti, is a prescription medicine that helps prevent migraine attacks in adults. It is a preventive treatment, meaning it is given on a schedule to reduce how often migraines happen, rather than taken to stop a migraine once it has started. People using it still keep a separate medicine on hand for attacks that break through. It is used for both episodic migraine (fewer than 15 headache days a month) and chronic migraine (15 or more headache days a month). It is one of four antibody medicines that target CGRP (calcitonin gene-related peptide), a chemical messenger involved in migraine. The others, Aimovig (erenumab), Ajovy (fremanezumab) and Emgality (galcanezumab), are injections people give themselves under the skin, while Vyepti is the only one given into a vein in a clinic. The American Headache Society considers these CGRP-targeting medicines a first-line choice for migraine prevention, so people do not need to have tried and failed older preventives first. Vyepti is not approved for children.
CGRP is made in large amounts by the trigeminal nerve, the main nerve carrying sensation from the head and face. In migraine, CGRP helps widen blood vessels around the brain and makes pain pathways more sensitive, so ordinary signals register as pain. Research on this signaling led to medicines built specifically to block it. Eptinezumab is a monoclonal antibody, a lab-made protein designed to latch onto one specific target. It binds to CGRP itself and stops it from attaching to its receptor, so less of that signal gets through. Because the antibody stays in the body for weeks (about half is gone after roughly 27 days), one infusion keeps working for the three months until the next dose. Blocking CGRP lowers the number of migraine days for many people, but it does not work for everyone, and it does not address every pathway involved in migraine.
Vyepti is given as an intravenous (IV) infusion, a slow drip through a small tube in a vein, at an infusion center or doctor's office. The infusion takes about 30 minutes and is repeated every 3 months. The usual dose is 100 mg; some people are moved to 300 mg if they need more effect. There is nothing to store or inject at home, which some people prefer over monthly self-injections, though it does mean scheduling a clinic visit four times a year. Staff watch for allergic reactions during the infusion, since that is when most occur. If an appointment is missed, contact the prescriber's office to reschedule rather than waiting for the next planned date.
Most people tolerate Vyepti well. In clinical trials, the most common side effects were cold-like symptoms such as a stuffy or runny nose and sore throat, and allergic-type reactions on the day of the infusion, such as itching, flushing or rash. Fatigue has also been reported. Allergic reactions usually happen during the infusion, where staff can stop it and treat them. Serious reactions, including anaphylaxis (a severe, whole-body allergic reaction), have been reported. If swelling of the face, lips, tongue or throat, or trouble breathing, starts after leaving the clinic, call 911. A milder reaction later on, such as hives, itching or a rash, should be reported to the prescriber right away. Anyone who has had a serious allergic reaction to eptinezumab should not receive it again. Constipation can occur, and in rare cases with this group of medicines it has become severe enough to need hospital care or surgery. It most often starts after the first dose but can appear later. Contact the care team about severe or worsening constipation, especially if you also take medicines that slow the gut, such as opioid pain medicines.
Because eptinezumab is an antibody broken down like other proteins, rather than processed by the liver enzymes that cause many drug interactions, it is unlikely to interfere with most other medicines. It has been given safely alongside sumatriptan, a common migraine attack medicine. Medicines that slow bowel movements can raise the risk of severe constipation, so mention them to the prescriber. New high blood pressure, or worsening of existing high blood pressure, has been reported with CGRP-blocking medicines, most often within the first week after starting, and sometimes needing treatment or hospital care. It is worth checking blood pressure, particularly early on, and telling the prescriber if readings rise. The main trials did not include people with heart disease, stroke or high blood pressure, so less is known about use in those groups. Raynaud's phenomenon, in which fingers or toes turn white or blue and feel cold, numb or painful, can start or worsen with this class of medicine. If these signs appear, stop treatment and contact the prescriber; symptoms usually improve after the medicine is stopped. People with a history of Raynaud's should discuss this before starting. There is too little information to know whether Vyepti is safe during pregnancy or breastfeeding, and the antibody lingers for months after an infusion. Anyone pregnant, planning pregnancy or breastfeeding should talk it through with the prescriber. A pregnancy registry tracks outcomes for people exposed during pregnancy.
Because the medicine goes straight into the bloodstream, it can start working quickly. In trials, fewer people had a migraine in the first days after the first infusion compared with placebo (a dummy treatment). The full effect is usually judged over the first few months, often after one or two infusions. Results vary. In the main trials, people with episodic migraine who started with about 9 migraine days a month had roughly 4 fewer migraine days a month, compared with about 3 fewer on placebo. People with chronic migraine who started with about 16 migraine days a month had roughly 8 fewer, compared with about 6 fewer on placebo. About half to 60 percent of people on Vyepti cut their migraine days at least in half, compared with under 40 percent on placebo. Some people improve a great deal, and some very little. Keeping a headache diary helps the prescriber judge whether the medicine is worth continuing. If it is not helping enough after a fair trial, options include the higher dose, switching to another preventive or combining approaches. How long to continue is decided case by case. There is no evidence that one CGRP antibody works better than another.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Vyepti (Eptinezumab), what you've noticed, or ask the community a question.